Información del artículo
El Texto completo está disponible en PDF
Referencias Bibliográficas
[1.]
G.L. Snider, J. Kleinreman, W.M. Thurlbeck, Z.H. Bengali.
The definition of emphysema: Report of the National Heart and Blood Institute, division of lung diseases, workshop.
Am Rev Respir Dis, 132 (1985), pp. 182-185
[2.]
J. Frías, M. Gomis, J. Prieto, J. Mensa, R. Bouza, J.A. García-Rodríguez, et al.
Tratamiento antibiótico empírico inicial de la neumonía adquirida en la comunidad.
Rev Esp Quimioter, 11 (1998), pp. 255-261
[4.]
V.S. Pena, M. Miravitlles, R. Gabriel, C.A. Jiménez-Ruiz, C. Villasante, J.F. Masa, et al.
Geographic variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC Multicentre Epidemiological Study.
Chest, 118 (2000), pp. 981-989
[5.]
F. Ballester, S. Pérez-Hoyos, M.L. Rivera, T. Merelles, J.M. Tenias, J.B. Soriano, et al.
Patrones de frecuentación y factores asociados al ingreso en el hospital de las urgencias hospitalarias por asma y enfermedad pulmonar obstructiva crónica.
Arch Bronconeumol, 35 (1999), pp. 20-26
[6.]
Grupo para el Estudio de la Infección en Urgencias.
Estudio epidemiológico de las infecciones en el Área de Urgencias.
Emergencias, 12 (2000), pp. 80-89
[7.]
M. Martínez Ortiz de Zárate.
Aspectos epidemiológicos de las infecciones en las Áreas de Urgencias.
Emergencias, 13 (2001), pp. S44-S50
[8.]
J. Vaqué.
Grupo de Trabajo EPINE. Evolución de la prevalencia de las infecciones nosocomiales en los hospitales españoles.
Proyecto EPINE 1990-1997,
[9.]
J.T. MacFarlane, A. Colville, A. Guion, R.M. MacFarlane, D.H. Rose.
Prospective study of aetiology and outcome of adult lower respiratory tract infections in the community.
Lancet, 341 (1993), pp. 511-514
[10.]
M. Woodhead, G. Gialdroni Grassi, G.J. Huchon, P. Léophonte, F. Manresa, T. Schaberg.
Use of investigations in lower respiratory tract infection in the community: A European survey.
Eur Respir J, 9 (1996), pp. 1596-1600
[11.]
G. Huchon, G. Gialdroni-Grassi, P. Léophonte, F. Manresa, T. Schaberg, M. Woodhead.
Initial antibiotic theropy for lower respiratory tract infection in the community: A European survey.
Eur Respir J, 9 (1996), pp. 1590-1595
[12.]
J. Romero Vivas, M. Rubio Alonso, O. Corral, S. Pacheco, E. Agudo, J.J. Picazo.
Estudio de las infecciones respiratorias extrahospitalarias.
Enferm Infecc Microbiol Clin, 15 (1997), pp. 289-298
[13.]
M. Miravitlles, C. Espinosa, E. Fernández-Laso, J.A. Martos, J.A. Maldonado, M. Gallego.
Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD.
Chest, 116 (1999), pp. 40-46
[14.]
J. Eller, A. Ede, T. Schaberg, M.S. Niederman, H. Mauch, H. Lode.
Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function.
Chest, 113 (1998), pp. 1542-1548
[15.]
E. Monsó, J. Ruiz, A. Rosell, J. Manterola, J. Fiz, J. Morera, et al.
Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush.
Am J Respir Crit Care Med, 152 (1995), pp. 1316-1320
[16.]
N. Soler, A. Torres, S. Ewig, J. González, R. Celis, M. El-Ebiary, et al.
Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation.
Am J Respir Crit Care Med, 157 (1998), pp. 1498-1505
[17.]
X. Xu, L. Wang.
Association of indoor and outdoor particulate pollution level with chronic respiratory illness.
Am Rev Respir Dis, 148 (1993), pp. 1516-1522
[18.]
D.P. Tashkin, R. Detels, M. Simmons.
The UCLA population studies of chronic obstructive pulmonary disease. XI.
Impact of air pollution and smoking on annual change in forced expiratory volume in one second Am J Respir Crit Care Med, 149 (1994), pp. 1067-1083
[19.]
American Thoracic Society.
Lung function testing: Selection of reference values and interpretative strategies.
Am Rev Respir Dis, 144 (1991), pp. 1202-1218
[20.]
J.A. Barberá, G. Peces Barba, A.G.N. Agustí, J.L. Izquierdo, E. Monso, T. Montemayor, et al.
Guía clínica para el diagnóstico y tratamiento de la enfermedad pulmonar obstructiva crónica.
Arch Bronconeumol, 37 (2001), pp. 297-316
[21.]
D.S. Postma.
When can an exacerbation of COPD be treated at home?.
Lancet, 351 (1998), pp. 1827-1828
[22.]
A. Chaouat, E. Weitzenblum, R. Kessler, C. Charpentier, M. Enhart, M. Schott, et al.
A randomized trial of nocturnal oxygen theropy in chronic obstructive pulmonary disease patients.
Eur Respir J, 14 (1999), pp. 1002-1008
[23.]
A.F.J. Connors, N.Y. Dawson, C. Thomas.
Outcomes following acute exacerbations of severe chronic obstructive lung disease.
Am J Respir Crit Care Med, 154 (1996), pp. 959-996
[24.]
M.S. Moya Mir, P. Laguna del Estal, R. Salgado Marqués, S. Calabrese Sánchez.
Infección respiratoria en observación de urgencias.
Emergencias, 9 (1997), pp. 98-102
[25.]
G.H. Murata, M.S. Gorby, T.W. Chick, A.K. Halperin.
Use of emergency medical services by patients with decompensated obstructive lung disease.
Ann Emerg Med, 18 (1989), pp. 501-506
[26.]
C.L. Emerman, D. Effron, T.W. Lukens.
Spirometric criteria for hospital admission of patients with acute exacerbation of COPD.
Chest, 99 (1991), pp. 595-599
[27.]
R. Kessler, M. Faller, G. Fourgaut, B. Mennecier, E. Weitzenblum.
Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 159 (1999), pp. 158-164
[28.]
D.A. Mahler, R.A. Rosiello, A. Harver, T. Lentine, J.F. McGovern, J.A. Daubenspeck.
Comparison of clinical dysnea ratings and psychophysical measurementes of respiratory sensation in obstructive airways disease.
Am Rev Respir Dis, 165 (1987), pp. 1229-1233
[29.]
J.Y. Fagon, J. Chastre, J.L. Trouillet, Y. Domart, M.C. Dombret, M. Bornet, et al.
Characterization of distal bronchial microflora during acute exacerbations of chronic bronchitis: Use of the protected specimen brush technique in 54 mechanically ventiaated patients.
Am Rev Respir Dis, 142 (1990), pp. 1004-1008
[30.]
H. Cabello, A. Torres, R. Celis, M. El-Ebiary, J. Puig de la Bellacara, D.M. Xaubet, et al.
Bacterial colonization of distal airways in healthy subjects and chronic lung disease: A bronchoscopic study.
Eur Respir J, 10 (1997), pp. 1137-1144
[31.]
S. Ewig, N. Soler, A. Torres.
Evaluation of antimicrobial treatment in patients with severe exacerbations of chronic pulmonary disease.
Clin Pulm Med, 6 (1999), pp. 1-8
[32.]
J.D. Heffelfinger, S.F. Dowell, J.H. Jorgensen, K.P. Klugman, L.R. Mabry, D.M. Musher, et al.
Management of community acquired pneumonia in the era of pneumococcal resistance: A report from drug-resistant Streptococcus pneumoniae. Therapeutic Working Group.
Arch Int Med, 160 (2000), pp. 1399-1408
[33.]
B. Rosón, J. Carratalá, R. Verdaguer, J. Dorca, F. Manresa, F. Gudiol.
Prospective study of the usefulness of Gram stain in the Initial approach to community-acquired pneumonia requiring hospitalization.
Clin Infect Dis, 31 (2000), pp. 869-874
[34.]
S. Chodosh.
Bronchitis and asthma.
Infectious Disease, pp. 476-485
[35.]
G. Lindsay, H.J. Scorer, C.M. Carnegie.
Safety and efficacy of temafloxacin versus ciprofloxacin in lower respiratory tract infections: A randomized, double-blind trial.
J Antimicrob Chemother, 13 (1992), pp. 89-100
[36.]
P. Ball, J.M. Harris, D. Lowson, G. Tillotson, R. Wilson.
Acute infective exacerbations of chronic bronchitis.
QJM, 88 (1995), pp. 61-68
[37.]
A. Anzueto, M.S. Niederman, G. Tillotson.
Etiology, susceptibility and treatment of acute bacterial exacerbations for complicated chronic bronchitis in the primary care setting: Ciprofloxacin 750mg b. id versus clarithromycin 500mg b.i.d.
Clin Ther, 20 (1998), pp. 885-890
[38.]
A.C. DeAbate, D. Henry, G. Beusch, A. Jubran, S. Chodosh, L. Harper, et al.
Sparfloxacin vs ofloxacin in the treatment of acute exacerbations of chronic bronchitis: A multicenter double-blind randomized comparative study.
Chest, 114 (1998), pp. 120-130
[39.]
G. Panckuch, M.A. Visalli, M. Jacobs, P. Appelbaum.
Susceptibilities of penicillin-and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents.
Antimicrob Agents Chemother, 42 (1998), pp. 624-630
[40.]
F. Baquero, J.A. García-Rodríguez, J. García de Lomas, L. Aguilar.
The Spanish Surveillance group: Antimicrobial resistance of 1113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: Results of a 1 year (1996-1997) multicenter surveillance study.
Antimicrob Agents Chemother, 43 (1999), pp. 357-359
[41.]
A. McGowan, M. Wootton, A. Holt.
The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility.
J Antimicrob Chemother, 43 (1999), pp. 345-349
[42.]
K. Madaras-Kelly, B. Ostergaard, L.B. Houde, J. Rotschafer.
Twenty fourhour area under the concentration-time curveIMIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
Antimicrob Agents Chemother, 40 (1996), pp. 627-632
[43.]
G. Bonflglio.
Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa?.
Chemotherapy, 47 (2000), pp. 239-242
[44.]
S. Yagel, J. Barret, D. Amaratunga, M. Frosco.
In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia.
Antimicrob Agents Chemother, 40 (1996), pp. 2894-2897
[45.]
H. Ishida, Y. Ishida, Y. Kurosaka, T. Otani, K. Sato, H. Kobayashi.
In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa.
Antimicrob Agents Chemother, 42 (1998), pp. 1651-1655
[46.]
E. Bouza, F. García-Garrote, E. Cercenado, M. Marín, M.S. Díaz.
Pseudomonas aeruginosa: A survey of resistance in 136 hospitals in Spain. The Spanish Pseudomonas aeruginosa Study Group.
Antimicrob Agents Chemother, 43 (1999), pp. 981-982
[47.]
J.R. May.
The bacteriology of chronic bronchitis.
Lancet, 351 (1953), pp. 534-537
[48.]
H.M. Pollock, E.L. Hawkins, J.R. Bonner, T. Sparkman, J.B.J. Bass.
Diagnosis of bacterial pulmonary infections with quantitative protected catheter cultures obtained during bronchoscopy.
J Clin Microbiol, 17 (1983), pp. 255-259
[49.]
J.Y. Fagon, J. Chastre, Y. Trouillet JL Dornort, M.C. Dombret, M. Bornet, C. Gibert.
Characterization of distal bronchial microflora during acute exacerbación of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients.
Am Rev Respir Dis, 142 (1990), pp. 1004-1008
[50.]
R. Zalacaín, V. Achotegui, L. Pascal, J. Camino, J. Barron, V. Sobradillo.
El cepillado protegido bacteriológico en pacientes con EPOC severa.
Arch Bronconeumol, 33 (1997), pp. 16-19
[51.]
T.F. Murphy.
Haemophilus influenzas in chronic bronchitis.
Semin Respir Infect, 15 (2000), pp. 41-51
[52.]
T.F. Murphy, S. Sethi.
Bacterial infection in chronic obstructive pulmonary disease.
Am Rev Respir Dis, 146 (1992), pp. 1067-1083
[53.]
D. Lehmann, K.J. Coakley, C.A. Coakley, V. Spooner, J.M. Montgomery, A. Michael, et al.
Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzas vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea.
Am Rev Respir Dis, 144 (1991), pp. 324-330
[54.]
M.K. Tandon, V.A. Gebski.
Controlled trial of a killed Haemophilus influenzas vaccine for prevention of acute exacerbations of chronic bronchitis.
Aust N Z J Med, 21 (1991), pp. 427-432
[55.]
R. Clancy, A. Cripps, K. Murree-Allen, S. Yeung, M. Engel.
Oral immunization with killed Haemophilus influenzas for protection against acute bronchitis in chronic obstructive lung disease.
Lancet, ii (1985), pp. 1395-1397
[56.]
R.L. Clancy, A.W. Cripps, V. Gebski.
Protection against recurrent acute bronchitis after oral immunization with killed Haemophilus influenzas.
Med J Aust, 152 (1990), pp. 413-416
[57.]
A.R. Foxwell, A.W. Cripps.
Haemophilus influenzas oral vaccination against acute bronchitis.
Cochrane Database Syst Rev, CD001958 (2000),
[58.]
M.B. Nelson, T.F. Murphy, H. van Keulen, D. Rekosh, M.A. Apicella.
Studies on P6, an important outer-membrane protein antigen of Haemophilus influenzas.
Rev Infect Dis, 10 (1988), pp. S331-S336
[59.]
J.M. Kyd, M.L. Dunkley, A.W. Cripps.
Enhanced respiratory clearance of nontypeable Haemophilus influenzas following mucosal immunization with P6 in a rat model.
Infect Immun, 63 (1995), pp. 2931-2940
[60.]
Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR, 46 (1997), pp. 1-24
[62.]
A. Bacle, P. Diot, E. Lemarie.
Vaccin anti-pneumococcique. Justifications et resultats.
Rev Pneumol Clin, 53 (1997), pp. 128-137
[63.]
D.W. Gump, C.A. Phillips, B.R. Forsyth, K. McIntosh, K.R. Lamborn, W.H. Stouch.
Role of infection in chronic bronchitis.
Am Rev Respir Dis, 113 (1976), pp. 465-474
[64.]
R.O. Buscho, D. Saxtan, P.S. Shultz, E. Finch, M.A. Mufson.
Infections with viruses and Mycoplasma pneumoniae during exacerbations of chronic bronchitis.
J Infect Dis, 137 (1978), pp. 377-383
[65.]
C.B. Smith, C.A. Golden, R.E. Kanner, A.D.J. Renzetti.
Association of vital and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases.
Am Rev Respir Dis, 121 (1980), pp. 225-232
[66.]
N. Soler, A. Torres, S. Ewig, J. Gonzalez, R. Celis, M. El-Ebiary, et al.
Bronchial microbial pattems in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation.
Am J Respir Crit Care Med, 157 (1998), pp. 1498-1505
[67.]
E.J. Poole, E. Chacko, R.W.B. Wood-Baker, C.J. Cates.
Influenza vaccine for patients with chronic obstructive pulmonary disease (Cochrane review), vol. 1.
Cochrane Library, Oxford, Update Software, (2001),
[68.]
A.H. Ahmed, K.G. Nicholson, J.S. Nguyen-van Tam, J.C. Pearson.
Effectiveness of influenza vaccine in reducing hospital admissions during the 1989-90 epidemic.
Epidemiol Infect, 118 (1997), pp. 27-33
Copyright © 2003. Elsevier España, S.L. y Sociedad Española de Medicina Rural y Generalista (SEMERGEN)
